Avidity Biosciences, Inc.
RNA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $11 | $10 | $9 | $9 |
| % Growth | 14% | 3.6% | -1.1% | – |
| Cost of Goods Sold | $0 | $2 | $1 | $101 |
| Gross Profit | $11 | $7 | $8 | -$92 |
| % Margin | 100% | 78% | 85% | -984.9% |
| R&D Expenses | $304 | $191 | $150 | $101 |
| G&A Expenses | $86 | $54 | $38 | $26 |
| SG&A Expenses | $86 | $54 | $38 | $26 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$2 | -$1 | -$101 |
| Operating Expenses | $390 | $243 | $187 | $26 |
| Operating Income | -$379 | -$236 | -$179 | -$118 |
| % Margin | -3,477.4% | -2,464.4% | -1,939.6% | -1,265.8% |
| Other Income/Exp. Net | $57 | $23 | $5 | $0 |
| Pre-Tax Income | -$322 | -$212 | -$174 | -$118 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$322 | -$212 | -$174 | -$118 |
| % Margin | -2,957.7% | -2,219.9% | -1,886.3% | -1,265.4% |
| EPS | -2.89 | -2.91 | -3.34 | -2.85 |
| % Growth | 0.7% | 12.9% | -17.2% | – |
| EPS Diluted | -2.89 | -2.91 | -3.34 | -2.85 |
| Weighted Avg Shares Out | 112 | 73 | 52 | 41 |
| Weighted Avg Shares Out Dil | 112 | 73 | 52 | 41 |
| Supplemental Information | – | – | – | – |
| Interest Income | $57 | $24 | $5 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $3 | $2 | $1 | $1 |
| EBITDA | -$376 | -$233 | -$178 | -$117 |
| % Margin | -3,452% | -2,442.4% | -1,924.6% | -1,259% |